Cell-free DNA (cfDNA) analysis is transforming precision medicine, offering a non-invasive window into the body, particularly in the context of cancer. This journal collection, hosted by npj Precision ...

SAGA Diagnostics has commercially launched its Pathlight test in the US to detect residual disease and recurrence. Comprising a multi-cancer molecular residual disease (MRD) platform, the test has ...

Sumitomo Pharma America, Inc. (SMPA) today presented new clinical data supporting further development of enzomenib, an investigational, oral selective menin inhibitor being researched for the ...